Loading...
01/10 22:43
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call shows strong financial performance with record high revenues and significant annual contract value plus royalties. Despite operational losses, improvements were noted, and guidance remains optimistic. The Q&A section highlighted strong product adoption and positive ASP trends. However, management's lack of clarity on specific bookings figures slightly tempers enthusiasm. Overall, the positive financial metrics and guidance suggest a likely stock price increase in the short term.
Total Revenue $15.5 million, up 24% year-over-year.
Annual Contract Value plus Royalties $65.1 million, record high for the company.
Remaining Performance Obligations (RPO) $88.4 million, representing a 22% year-over-year increase.
Non-GAAP Gross Profit $14.2 million, representing a gross margin of 91%.
GAAP Gross Profit $13.9 million, representing a gross margin of 90%.
Non-GAAP Operating Expense $16.9 million, flat sequentially and only 1% higher year-over-year.
GAAP Operating Expense $21 million, representing a 4% year-over-year increase.
Non-GAAP Operating Loss $2.8 million, improved by $2.7 million compared to a loss of $5.5 million in the prior year.
GAAP Operating Loss $7.1 million, improved from a loss of $9.2 million in the prior year.
Non-GAAP Net Loss $3.9 million, or diluted net loss per share of $0.10.
GAAP Net Loss $8.2 million, or diluted net loss per share of $0.20.
Cash, Cash Equivalents and Investments $52.3 million, with no financial debt.
Free Cash Flow Negative $2.7 million in the fourth quarter, below guidance due to short-term working capital timing changes.
New Product Launch: FlexGen Smart NoC IP announced, offering up to 10x engineering productivity and significant power consumption reduction.
Product Adoption: Over 75% of FlexNoC Interconnect IP customers chose the advanced FlexNoC 5 version introduced 1.5 years ago.
Market Expansion: Strategic expansion into microcontroller (MCU) space with Infineon standardizing on Arteris NoC for automotive MCUs.
Customer Acquisition: 14 new customers added, including major players in AI and automotive sectors.
Operational Efficiency: Non-GAAP operating loss improved to $2.8 million in Q4 2024, a $2.7 million improvement year-over-year.
Strategic Shift: Partnership with MIPS to provide a preverified RISC-V reference platform to enhance interoperability.
Competitive Pressures: Arteris faces competitive pressures in the semiconductor IP market, particularly as they expand into new verticals like microcontrollers and AI-driven applications. The need to maintain superior performance and efficiency is critical to fend off competition from other technology providers.
Regulatory Issues: The company operates in a highly regulated industry, and any changes in regulations could impact their operations and product offerings. Compliance with these regulations is essential to avoid potential legal and financial repercussions.
Supply Chain Challenges: There are ongoing supply chain challenges that could affect the availability of components necessary for Arteris' products. Disruptions in the supply chain could lead to delays in product delivery and impact customer satisfaction.
Economic Factors: Economic fluctuations, including changes in demand for semiconductor products and overall market conditions, could adversely affect Arteris' revenue and growth prospects. The company must navigate these economic uncertainties to sustain its business.
Operational Risks: The company has reported non-GAAP operating losses, indicating potential operational inefficiencies. Continued focus on managing operating expenses is necessary to improve financial performance.
Annual Contract Value plus Royalties: Achieved a record of $65.1 million in Q4 2024, driven by increased adoption of AI-driven enterprise computing and automotive SoCs.
Customer Expansion: Significant wins included a global top five technology company and major automotive OEMs expanding their use of Arteris products.
Microcontroller Expansion: Strategically expanding into the MCU space, with Infineon standardizing on Arteris NoC for automotive MCUs.
FlexGen Smart NoC IP: Announced FlexGen, which automates high-performance NoC designs, improving productivity and reducing power consumption.
Partnership with MIPS: Announced a partnership to provide a preverified RISC-V reference platform to support mutual customers.
Q1 2025 Revenue Guidance: Expected revenue of $15.7 million to $16.1 million.
Q1 2025 Non-GAAP Operating Loss Guidance: Expected non-GAAP operating loss of $4 million to $3 million.
Full Year 2025 Revenue Guidance: Expected revenue of $66.0 million to $70 million.
Full Year 2025 Non-GAAP Operating Loss Guidance: Expected non-GAAP operating loss of between $12.5 million to $8.5 million.
Full Year 2025 Free Cash Flow Guidance: Expected positive free cash flow of $1 million to $7 million.
Share Repurchase Program: None
The earnings call summary shows strong financial performance with significant revenue growth, high gross margins, and positive free cash flow. The Q&A highlights opportunities with major companies like AMD and Altera, and the focus on AI and data centers is promising. The management's avoidance of booking details is a minor concern, but overall, the optimistic guidance, strong partnerships, and strategic investments suggest a positive outlook for the stock price.
The earnings call reveals strong financial performance with a 13% increase in revenue and a 15% rise in ACV plus royalties, reflecting growing demand. Record high revenue and strategic wins with major clients like AMD are positive indicators. While there are some concerns about expenses, the optimistic guidance for revenue and cash flow, alongside strategic partnerships and product developments, suggests a positive outlook. However, the lack of clarity on certain metrics in the Q&A slightly tempers enthusiasm, but the overall sentiment remains positive, likely leading to a stock price increase of 2% to 8%.
The earnings call presents mixed signals: record high revenue and strong ACV growth are positive, but operational losses and increased expenses due to currency fluctuations are concerning. Management's optimistic guidance is tempered by geopolitical risks and trade uncertainties. The Q&A reveals steady licensing activity and potential growth in FlexGen, but no acceleration in decision timelines. The lack of guidance on book-to-bill ratio is a red flag. Given these factors, a neutral stock price movement is likely, as positives are balanced by risks and uncertainties.
The earnings call shows strong financial performance with record high revenues and significant annual contract value plus royalties. Despite operational losses, improvements were noted, and guidance remains optimistic. The Q&A section highlighted strong product adoption and positive ASP trends. However, management's lack of clarity on specific bookings figures slightly tempers enthusiasm. Overall, the positive financial metrics and guidance suggest a likely stock price increase in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
